Introduction
Wegener's granulomatosis (WG) is a potentially lifethreatening, chronic inflammatory and autoimmune disease of as yet unknown aetiology. It is characterized by granuloma formation and an autoimmune vasculitis associated with highly specific antineutrophil cytoplasmic autoantibodies (ANCAs) targeting proteinase 3 (PR3-ANCA) in European and Northern American vasculitis cohorts where nearly all patients with generalized WG produce PR3-ANCA. The presence of ANCA associated with small-vessel necrotizing vasculitis, characterized by a paucity of immunoglobulin deposits in the vessel walls, is also found in Churg-Strauss syndrome (CSS) and microscopic polyangiitis. Hence, WG, CSS and microscopic polyangiitis are coined ANCA-associated vasculitides. In contrast to WG, ANCA typically recognize myeloperoxidase (MPO-ANCA) in CSS (and microscopic polyangiitis), but are found less frequently. 1, 2 With a prevalence of approximately 24-157 per million in European populations, WG is rare. 3 WG is most likely of multifactorial origin primed by a complex interaction of extrinsic (for example, exposure to Staphylococcus aureus or crystalline silica 4, 5 ) and genetic factors. A major genomic risk locus for WG has been identified on chromosome 6p21.3 including the HLA-DPB1 gene. 6, 7, 8 Another HLA locus, HLA-DR, has also been linked to WG susceptibility. 9, 10 Other genetic risk factors for WG comprise a polymorphism in PTPN22, 11 which has been identified as a risk factor in different (auto)-immune disorders, and variations in the a1-antitrypsin gene. 12 In addition, several relatively small studies on the genetic background of WG have been published, results of which still need to be re-evaluated in additional populations. These include associations described for the cytotoxic T-lymphocyte-associated protein-4 (CTLA4), 13, 14 programmed cell death protein-1 (PD-1) 13 and a copy number polymorphism in FCGR3B, the gene for the low-affinity IIIb receptor of the Fc fragment of IgG. 15 In a genome-wide association study, the 18q22 chromosomal region was identified as harbouring a putative genetic risk factor in type 1 diabetes (T1D). A non-synonymous single-nucleotide polymorphism (SNP), Gly307Ser, within the gene for CD226 (also referred to as DNAX accessory molecule 1, DNAM-1) was significantly associated with T1D in large Caucasian populations comprising a low-to-modest effect size (overall case-control odds ratio (OR) ¼ 1.16), with the 307Ser allele predisposing to T1D. In addition, Grave's disease was associated with this allele at an even lower effect size (OR ¼ 1.10). 16 Subsequently, disease association of this SNP was confirmed in T1D and Grave's disease and was also shown in large Caucasian panels of multiple sclerosis (MS) and rheumatoid arthritis. 17, 18 Moreover, the latter study produced evidence that the Gly307Ser polymorphism is actually the causal variant of the associated genomic region.
CD226 belongs to the immunoglobulin supergene family of receptors. It is constitutively expressed on the majority of CD4 þ and CD8 þ T cells, natural killer cells, monocytes, a subset of B cells and platelets. It is involved in the adhesion and co-stimulation of T cells 19 and in the amplification of immune responses.
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CD226 is expressed on in vitro generated Th1 clones and has a role in natural killer cell-mediated cytotoxicity. The b 2 -integrin LFA-1 (CD11a/CD18), the poliovirus receptor (PVR/CD155) and PVR-related family-2 receptor (PRR-2/CD112) have been identified as ligands for CD226. 21 Interaction of CD226 with PVR has a role in endothelial transmigration of leukocytes, 22 and anti-CD226 treatment leads to delayed onset and an attenuated disease course in a mouse model of MS. 21 A profound alteration of the T-cell response including Th1 and Th17 responses, natural-killer-likeT-cells anomalously expressing natural killer-receptors, and dysfunctional regulatory T-cells is observed in WG. [23] [24] [25] [26] Thus, similar to T1D, MS and rheumatoid arthritis, in which distinct T-cell alterations are also common, CD226 polymorphisms could predispose to the altered T-cell response in WG.
To evaluate the impact of the CD226 Gly307Ser polymorphism in the etiopathology of WG, we genotyped it in a relatively large panel of German WG patients compared with ethnically matched healthy controls. We show a significant association of the 307Ser allele with WG, supported by concordant findings in WG panels from Southern Germany and the United Kingdom as well as in a German CSS cohort. Further, in a panel of German MS patients (n ¼ 422), we replicated association of the 307Ser allele with MS independently from the previous studies. 17, 18 Results and discussion
The minor allele (that is, 307Ser) frequency of the CD226 Gly307Ser polymorphism did not differ significantly between the three investigated control panels, which were in Hardy-Weinberg equilibrium throughout (as were all investigated case cohorts, see Table 1 ).The three control cohorts were therefore combined, then comprising 1226 individuals. In total, we found a minor allele frequency in our controls that is very similar to the one that has been described in UK and US control panels by Hafler et al. 18 where effects were restricted to ANCA þ WG subjects. Gly307Ser genotype did not correlate with age of onset in the WG panel (51.3±15.8 years for Gly/Gly carriers, 49.9 ± 16.1 years for heterozygous cases and 50.3±16.2 years for ser/ser carriers). Furthermore, there were no significant differences in the frequency of kidney or lung involvement between the three genotypes. Calculated against UK control data from Hafler et al. 18 (allele frequency of CD226 307Ser ¼ 0.47, n ¼ 9337).
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To support the role of the 307Ser in WG, we then genotyped the SNP in an additional patient panel from Southern Germany (n ¼ 122), revealing an even higher frequency of the 307Ser allele (0.53) leading to a significant association when compared with the same control group (P ¼ 0.02, OR ¼ 1.37, 95% CI ¼ 1.05-1.78, Table 1 ). Combining these two German WG panels produced an even stronger association of this allele with WG (P ¼ 0.0031, OR ¼ 1.23, 95% CI ¼ 1.07-1.40, Table 1 ). Yet, such calculations have to be taken with caution, as we cannot exclude a geographical impact when comparing the Southern Germany WG patients with Northern and Western German controls.
Subsequently, we genotyped a third WG panel (n ¼ 105) from Birmingham, UK, for which unfortunately no geographically matched control cohort was available. Nonetheless, the fact that the 307Ser allele was again found with a clearly increased frequency (0.51, OR ¼ 1.17 when compared with the panel of 9377 British controls genotyped by Hafler et al.,
18 Table 1 ) supports the existence of a true association of the Gly307Ser SNP with WG. Again, the age at WG diagnosis was not significantly different between the three genotypes (55.4±19.9 years for gly/gly carriers, 50.1±16.0 years for gly/ser and 54.0 ± 16.9 years for ser/ser carriers), neither was the frequency of kidney or lung involvement. Finally, to investigate the role of CD226 in other ANCA-associated vasculitides, we genotyped the Gly307Ser SNP in 119 patients diagnosed with CSS, which were also recruited at the University of Lü beck/ Klinikum Bad Bramstedt, Germany. Again, we found an increased frequency of the 307Ser allele (0.50) producing a very similar OR as in WG (OR ¼ 1.20, 95% CI ¼ 0.92-1.56, Table 1 ). Both the effects observed in the British WG panel and the German CSS cohort did not reach significance level, which is apparently because of the relatively small size and reduced statistical power (see Table 1 ).
As the Gly307Ser SNP was also found associated with MS in two large study sets, 17, 18 we additionally investigated this variation in a panel of 422 unrelated German MS patients. Similar to the results for WG and CSS, the frequency of the 307Ser allele was increased in comparison with the German controls (0.50, P ¼ 0.011, OR ¼ 1.22, 95% CI ¼ 1.05-1.43, Table 1 ). Thus, given the fact that the two aforementioned data sets were partially overlapping, 17, 18 we present here the first replication of the suggested association of this SNP with MS in an entirely independent cohort. Further, although samples from Belgium, Norway and Sweden were included in the previous analyses in addition to US and UK samples, 16 we show here an association of this SNP with MS in a German cohort, suggesting that it may confer (modest) risk for MS across various European populations. Finally, we performed a combined analysis of all German patients involved in this study (that is, WG, CSS and MS). The CD226 307Ser allele was highly significantly over-represented in this combined case panel (P ¼ 0.00049), further supporting an overlapping risk effect of this allele in the susceptibility to (auto)immune diseases.
The exact functional consequence of the Gly307Ser exchange within the CD226 protein still has to be elucidated. It has been hypothesized that the amino-acid exchange could disrupt a splice-site enhancer or silencer, thereby altering RNA splicing, resulting in a putative CD226 isoform acting either as a non-functional protein or as a protein with a novel function. 16 Alternatively, this amino-acid substitution could alter the signalling cascade by affecting the two known phosphorylation sites at positions 322 and 329, which are important in CD226-mediated signalling. 18 As anomalously exaggerated Th1 and Th17 responses of total CD4 þ and autoantigenspecific T-cell populations have been reported in T1D, MS and rheumatoid arthritis, as well as in WG, alterations of CD226-mediated signalling could contribute to alterations of the T-cell response in these diseases. 25, [27] [28] [29] [30] [31] Patients and methods
Patients
In all, 520 unrelated patients with WG (259 male and 261 female individuals) according to the criteria of the American College of Rheumatology and the Chapel Hill consensus conference 32 were included in the initial genotyping phase. All of them were of German decent and were recruited from the vasculitis centre of the University of Lü beck and Klinikum Bad Bramstedt. ANCA status was determined as described earlier 33 35 were recruited at the Department of Neurology, St Josef Hospital, Ruhr University, Bochum/Western Germany. Ethical principles for medical research involving human subjects as defined in the Declaration of Helsinki have been followed. The study design was approved by the local ethics committee at the University of Lü beck, Germany (nos. AZ05-219 and 06-087), the South Birmingham, UK research ethics committee (reference no. 0723), and the University of Bochum, Germany (no. 1515), respectively. Genotyping A commercially available TaqMan genotyping assay (Applied Biosystems, Darmstadt, Germany) was used for genotyping of the CD226 SNP. All reactions were carried out with TaqMan Genotyping MasterMix (Applied Biosystems) on a StepOne Plus realtime PCR cycler (Applied Biosystems) according to the manufacturer's instructions.
Data analysis
Allele frequencies were compared between patients and controls by w 2 -tests on contingency tables. A P-value o0.05 was considered significant. Power analyses were performed for the individual comparisons by using Quanto 1.2.3 (http://hydra.usc.edu/gxe/), 36 taking as basis a log-additive model, the effect size (OR) found in the respective panels and a significance threshold of Po0.05 (one-sided test).
